Compare GBDC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBDC | ADMA |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 2010 | N/A |
| Metric | GBDC | ADMA |
|---|---|---|
| Price | $14.34 | $19.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $14.83 | ★ $28.50 |
| AVG Volume (30 Days) | 1.4M | ★ 3.1M |
| Earning Date | 11-18-2025 | 11-05-2025 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | 4.09 | ★ 205.35 |
| EPS | ★ 1.42 | 0.86 |
| Revenue | ★ $870,777,000.00 | $488,559,000.00 |
| Revenue This Year | N/A | $22.19 |
| Revenue Next Year | N/A | $24.33 |
| P/E Ratio | ★ $10.15 | $23.34 |
| Revenue Growth | 20.16 | ★ 27.63 |
| 52 Week Low | $12.68 | $13.50 |
| 52 Week High | $16.01 | $25.67 |
| Indicator | GBDC | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 63.98 | 72.64 |
| Support Level | $14.22 | $19.13 |
| Resistance Level | $14.41 | $20.22 |
| Average True Range (ATR) | 0.15 | 0.76 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 92.18 | 95.92 |
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.